Acumed competitors

Scott Flora has more than 40 years of healthcare experience in surgical devices and is currently serving as Board Chair for Palliare Ltd and New View Surgical. He is also on the Board of Conventus/Flower Orthopaedics. Prior to that Scott held the following leadership roles, Interim President and CEO of Invuity, Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group ,President Smith& Nephew Orthopedic Reconstruction, General Manager Smith&Nephew Trauma , Sr. V.P. Sales US and Europe, Global V.P. Sales & Marketing Ioptex Research. Scott has also served on three public company boards, Invuity, MAKO Surgical and Tengion. Scotts skills have been demonstrated in:Building Effective TeamsInnovation ManagementResults OrientedStrategic AgilityBuilding a Strong Vision supported by ValuesGlobal LeadershipCommercial ExecutionGovernance

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Ed was named president & chief executive officer of Owens & Minor, effective March 7, 2019, and was appointed to the board of directors at the same time. Prior to that, Ed served as an independent consultant and advisor in the healthcare, life science and distribution industries since January 2016. From January 2000 through April 2015, he served in various roles of increasing responsibility at Thermo Fisher Scientific, a $17 billion manufacturer and supplier of a range of products to the research, healthcare, industrial and safety markets, including most recently as chief commercial officer & senior vice president. Before joining Thermo Fisher Scientific, Ed spent eight years at TRW Inc., in a variety of finance roles and three years with PricewaterhouseCoopers as an auditor.

Kevin serves as the fifth Chairman and CEO at Stryker since it was founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon. Stryker is a leading medical technology company with over 40,000 employees. Kevin was born in India, grew up in Canada, and has lived and worked in four countries and four industries. He is the current chair of AdvaMed (Med-Tech trade association) and is a member of the Business Roundtable and Business Council. He is also active with community boards.

Prior to joining Zimmer Biomet, Mr. Hanson served as a member of Medtronic’s Executive Committee and as Executive Vice President and Group President, Minimally Invasive Therapies Group of Medtronic, where he oversaw and provided strategic direction to that approximately $9 billion business. Prior to joining Medtronic, Mr. Hanson served as Group President, Covidien, with global responsibility for all Covidien business segments. Prior to being elevated to that newly created position, Mr. Hanson served as Group President, Medical Devices & U.S. of Covidien and prior to that, he served as Group President, Surgical Solutions and President, Energy-based Devices. Mr. Hanson began his career with Covidien in 1992. He holds a Bachelor of Science degree in Finance from Florida State University. He also completed the Kellogg School of Management Finance for Executives program in 2010 and the Harvard Executive Education in Leadership program in 2013. Mr. Hanson serves on the board of the Advanced Medical Technology Association (AdvaMed), the medical device industry’s association and is a member of the International Board Committee. He also serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.

Andy Eckert is a proven leader across multiple sectors of healthcare, including Medical Devices, HCIT and Services. Most recently, Andy was the CEO of Acelity, a leading provider of innovative wound care solutions and products. Under Andy’s leadership, Acelity increased its investment in R&D and new product commercialization, resulting in an impressive acceleration of top-line growth and the sale to 3M in 2019 for $6.7B. Prior to Acelity, Andy served as CEO of TriZetto, the leading enterprise software solution for commercial payors, where he sharpened the company’s strategic focus and guided TriZetto to a successful sale to Cognizant in 2014 for $2.7B. In addition, Andy has recently served as CEO of Valence Health, an emerging leader in value-based healthcare, and Chairman and CEO of CRC Health Group, a leading behavioral health treatment provider now part of Acadia. Earlier in his career, Andy was CEO of Eclipsys Corporation and CEO of SumTotal. He began his career at ADAC Laboratories, including four years as Chairman and CEO until its sale to Philips Medical Systems in 2000. Andy has also served on a number of corporate boards and is currently the Chairman of Varian Medical Systems (NYSE: VAR and a Director at Becton, Dickinson and Company (NYSE: BDX). He has a Bachelor of Science in Industrial Engineering and a Master of Business Administration, both from Stanford University.

Takaaki Ueda is a Chairman/CEO at SONOSITE INC, Pres & CEO:New Development USA at Fujifilm Holdings, and President/CEO at FUJIFILM Medical Systems USA Inc. He has worked as Gen Mgr:Global Endoscopy Systems at Fujifilm Holdings.